Top Banner
28
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Malaria Incidence and business oppurunity
Page 2: Malaria Incidence and business oppurunity

IncidenceIncidence Malaria is a common and life-threatening disease in Malaria is a common and life-threatening disease in

many tropical and subtropical areas and is currently many tropical and subtropical areas and is currently endemic in over 100 countries.endemic in over 100 countries.

Worldwide there are up to 30- 50 crore cases of malaria Worldwide there are up to 30- 50 crore cases of malaria each year; out of which 27 lakh die of it.each year; out of which 27 lakh die of it.

According to WHO, more than 90% of the deaths of According to WHO, more than 90% of the deaths of African children are due to malaria, which kills an African African children are due to malaria, which kills an African child in every 10 seconds.child in every 10 seconds.

Malaria is caused by a protozoan known as plasmodium, Malaria is caused by a protozoan known as plasmodium, among the hundreds of species of which only four are among the hundreds of species of which only four are known to affect humans, these are- P. vivax, P. known to affect humans, these are- P. vivax, P. falciparum, P. Ovule, P.malariae.falciparum, P. Ovule, P.malariae.

Page 3: Malaria Incidence and business oppurunity
Page 4: Malaria Incidence and business oppurunity

Region wise Status :-Region wise Status :-

Page 5: Malaria Incidence and business oppurunity

South East AsiaSouth East Asia

1. 1. INDONESIAINDONESIA CapitalCapital: Jakarta: Jakarta MalariaMalaria:: malaria risk exists all throughout the year in the whole malaria risk exists all throughout the year in the whole

country except Jakarta municipality, big cities, and within the country except Jakarta municipality, big cities, and within the areas of tourist resorts of Bali & Java. P. falciparum resistant to areas of tourist resorts of Bali & Java. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported. P. vivax chloroquine and sulfadoxine–pyrimethamine reported. P. vivax resistant to chloroquine reported.resistant to chloroquine reported.

2. MALAYSIA Capital: Kuala Lumpur Malaria: Malaria risk exists only in limited foci in the

deep hinterland. Urban and coastal areas are free from malaria. P. falciparum throughout the year. P. falciparum resistant to chloroquine and sulfadoxine-pyrimethamine reported.

Page 6: Malaria Incidence and business oppurunity

3. 3. MYANMAR (FORMERLY BURMA)MYANMAR (FORMERLY BURMA) CapitalCapital YangonYangon Malaria:Malaria: Malaria risk—predominantly due toP. falciparum—exists throughout the Malaria risk—predominantly due toP. falciparum—exists throughout the

year at altitudes below 1000 m, excluding the main urban areas of Yangon and year at altitudes below 1000 m, excluding the main urban areas of Yangon and Mandalay. Risk is highest in remote rural, hilly and forest areas. P. falciparum Mandalay. Risk is highest in remote rural, hilly and forest areas. P. falciparum resistant to chloroquine and sulfadoxine pyrimethamine reported. Mefloquine resistant to chloroquine and sulfadoxine pyrimethamine reported. Mefloquine resistance.resistance.

4. 4. THAILANDTHAILAND Capital:Capital: Bangkok Bangkok Malaria:Malaria: Malaria risk exists throughout the year in rural, especially Malaria risk exists throughout the year in rural, especially

forested and hilly, areas of the whole country, mainly towards the forested and hilly, areas of the whole country, mainly towards the international borders. There is no risk in cities and the main tourist resorts international borders. There is no risk in cities and the main tourist resorts (e.g. Bangkok, Chiangmai, Pattaya,Phuket, Samui). P. falciparum (e.g. Bangkok, Chiangmai, Pattaya,Phuket, Samui). P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported. resistant to chloroquine and sulfadoxine–pyrimethamine reported. Resistance to mefloquine and to quinine reported from areas near the Resistance to mefloquine and to quinine reported from areas near the borders with Cambodia and Myanmar. borders with Cambodia and Myanmar.

Page 7: Malaria Incidence and business oppurunity

SAARC CountriesSAARC Countries

1. Sri Lanka1. Sri Lanka

Capital:Capital: ColomboColomboMalaria:Malaria: Malaria risk—predominantly due to P. falciparum—exists Malaria risk—predominantly due to P. falciparum—exists throughout the year in all low veld areas (mainly Big Bend, Mhlume, throughout the year in all low veld areas (mainly Big Bend, Mhlume, Simunye and Tshaneni). Chloroquine-resistant P. falciparum reported. Simunye and Tshaneni). Chloroquine-resistant P. falciparum reported.

Page 8: Malaria Incidence and business oppurunity

East and Central AFRICAEast and Central AFRICA1. 1. ANGOLAANGOLA Capital:Capital: LuandaLuanda Malaria:Malaria: Malaria risk—predominantly due to P. falciparum—exists Malaria risk—predominantly due to P. falciparum—exists

throughout the year in the whole country. P. falciparum resistant to throughout the year in the whole country. P. falciparum resistant to chloroquine and sulfadoxine – pyrimethamine reported.chloroquine and sulfadoxine – pyrimethamine reported.

Market Information:-Market Information:- ## PopulationPopulation : : 13,931,155.13,931,155. # The transmission season is from October to October.

2. 2. CAMEROONCAMEROON Capital:Capital: YaoundéYaoundé Malaria:Malaria: Malaria risk—predominantly due to P. falciparum—Malaria risk—predominantly due to P. falciparum—

exists throughout the year in the whole country. P. falciparum exists throughout the year in the whole country. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine resistant to chloroquine and sulfadoxine–pyrimethamine reported.reported.

Market Information:Market Information: # Population : 8,376,571

Page 9: Malaria Incidence and business oppurunity

3. 3. ETHIOPIAETHIOPIA CapitalCapital Addis AbabaAddis Ababa MalariaMalaria: : Malaria risk—predominantly due to P. falciparum—exists Malaria risk—predominantly due to P. falciparum—exists

throughout the year in the whole country below 2000 m. P. falciparum throughout the year in the whole country below 2000 m. P. falciparum resistance to chloroquine and sulfadoxine-pyrimethamine reported. resistance to chloroquine and sulfadoxine-pyrimethamine reported. There is no malaria risk in Addis Ababa.There is no malaria risk in Addis Ababa.

Market informationMarket information: :

# Population : 65,976,703 (2002).# Population : 65,976,703 (2002).

# The Global Fund has approved an amount of # The Global Fund has approved an amount of US$ 37,915,012US$ 37,915,012 to reduce to reduce Malaria in Ethiopia for a period of two years.Malaria in Ethiopia for a period of two years.

Page 10: Malaria Incidence and business oppurunity

4. 4. KENYAKENYA Capital:Capital: Nairobi Nairobi MalariaMalaria:: Malaria risk—predominantly due to Malaria risk—predominantly due to

P. falciparum—exists throughout the year in theP. falciparum—exists throughout the year in the

whole country. There is normally little risk in the whole country. There is normally little risk in the

city of Nairobi and in the highlands (above 2500city of Nairobi and in the highlands (above 2500

m) of Central, Eastern, Nyanza, Rift Valley andm) of Central, Eastern, Nyanza, Rift Valley and

Western provinces. P. falciparum resistant to Western provinces. P. falciparum resistant to

chloroquine and sulfadoxine–pyrimethaminechloroquine and sulfadoxine–pyrimethamine

reported.reported. Market InformationMarket Information: :

# Population a: 32,020,244.# Population a: 32,020,244.

# The Global Fund has approved an amount of# The Global Fund has approved an amount of

US$ 10,526,880US$ 10,526,880 for a period of two years for the for a period of two years for the

project submitted by Kenya to address and reduceproject submitted by Kenya to address and reduce

the impact of malaria.the impact of malaria.

# Population at Risk of malaria 100%# Population at Risk of malaria 100%

Page 11: Malaria Incidence and business oppurunity

5. 5. MOZAMBIQUEMOZAMBIQUE CapitalCapital Maputo Maputo Malaria:Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in the Malaria risk—predominantly due to P. falciparum—exists throughout the year in the

whole country. P. falciparum resistant to chloroquine and sulfadoxine – pyrimethamine whole country. P. falciparum resistant to chloroquine and sulfadoxine – pyrimethamine reported.reported.

Market Information: Market Information: Population: 19,034,729. Global Fund support to fight Malaria:

The Global Fund has approved an amount of US$ 12,273,573 for a period of two years to accelerate

access to prevention, care, support and treatment for persons affected with malaria. Mozambique is also

part of the Multi-Country Southern Africa (South Africa Mozambique, Swaziland) support from the Global

Fund through the project "Malaria Control in the Lubombo Spatial Development Initiative Area". They

received US$7,424,815 for a period of two years. Malaria Transmission Season: The duration of malaria transmission is 2-9 months across the country, from

November to July. There is no area where the transmission is all year.

6. 6. NIGERIANIGERIA CapitalCapital AbujaAbuja Malaria:Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in the Malaria risk—predominantly due to P. falciparum—exists throughout the year in the

whole country. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine whole country. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported.reported.

Present statusPresent status:: Talks are going on with new contact for the distribution of Diagnostic Talks are going on with new contact for the distribution of Diagnostic products. products.

Page 12: Malaria Incidence and business oppurunity

7. MADAGASCAR Capital: Antananarivo Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country, with the highest risk in the coastal areas. Resistance to chloroquinereported. Market Information:- # Population : 16,959,026. # The Global Fund has approved an amount ofUS$ 1,500,000 for a period of two years for theprevention of malaria through Social Marketing inMadagascar.# Population at Risk of malaria 100%

Page 13: Malaria Incidence and business oppurunity

8 .8 .TANZANIATANZANIA CapitalCapital: : DodomaDodoma Malaria:Malaria: Malaria risk—predominantly due Malaria risk—predominantly due to P. falciparum—exists throughout the year to P. falciparum—exists throughout the year in the whole country below 1800 m. in the whole country below 1800 m. Market InformationMarket Information::# Population : 36,968,928.# Population : 36,968,928.# Global Fund support to fight Malaria:# Global Fund support to fight Malaria:The Global Fund has also approved an amountThe Global Fund has also approved an amount of of US$781,220US$781,220 for a period of two years for for a period of two years for the project for the implementation of new malariathe project for the implementation of new malaria treatment policy in Zanzibar.treatment policy in Zanzibar.# Population at Risk of malaria 100%# Population at Risk of malaria 100%

Page 14: Malaria Incidence and business oppurunity

Franco Phonic AfricaFranco Phonic Africa

1. 1. BENINBENIN CapitalCapital Porto-Novo (constitutional) /Porto-Novo (constitutional) / Cotonou (seat of Government)Cotonou (seat of Government)

Malaria:Malaria: Malaria risk—predominantly due to P. fMalaria risk—predominantly due to P. fexists throughout the year in the whole country. Resistance exists throughout the year in the whole country. Resistance to chloroquine and sulfadoxine - pyrimethamine reported.to chloroquine and sulfadoxine - pyrimethamine reported.

Market Information:• Population: 6,752,569 (2002)• Population at Risk of malaria is 100%• The Global Fund has approved an amount ofUS$ 2,389,185 to accelerate the fight against malariawithin the context of Roll Back Malaria Programme inBenin for two years.

Page 15: Malaria Incidence and business oppurunity

2. 2. BURKINA FASOBURKINA FASO CapitalCapital OuagadougouOuagadougou MalariaMalaria: : Malaria risk—predominantly due to P. falciparumMalaria risk—predominantly due to P. falciparum

exists throughout the year in the whole country. Resistance exists throughout the year in the whole country. Resistance

to chloroquine and sulfadoxine-pyrimethamineto chloroquine and sulfadoxine-pyrimethamine

reported.reported. Market information:# Population: 12,251,743 (2002)# Population at Risk of malaria N/A.# The Global Fund has approved an amount of

US$ 7,499,088 to enhance the control of Malaria in Burkina Faso for a period of two years.

Page 16: Malaria Incidence and business oppurunity

3. 3. CHADCHAD CapitalCapital: : N’DjamenaN’Djamena MalariaMalaria: : Malaria risk-predominantly due to P.fMalaria risk-predominantly due to P.f

exists throughout the year in the whole country.exists throughout the year in the whole country.

Resistance to chloroquine and sulfadoxine-Resistance to chloroquine and sulfadoxine-

pyrimethamine reported.pyrimethamine reported.

Market InformationMarket Information::

# Population : 8,376,571 (2002)# Population : 8,376,571 (2002)

# Population at Risk of malaria: N/A

# Global Fund support to fight MALARIA,the country has applied for the third round.

Page 17: Malaria Incidence and business oppurunity

4.4. GUINEAGUINEA CapitalCapital ConakryConakry Malaria:Malaria: Malaria risk—predominantly due to P. fMalaria risk—predominantly due to P. f

——exists throughout the year in the parts of the interior. exists throughout the year in the parts of the interior.

Sporadic cases of malaria have been reported from the Sporadic cases of malaria have been reported from the

densely populated coastal belt. Chloroquine-resistant densely populated coastal belt. Chloroquine-resistant

P. falciparum reported.P. falciparum reported. Market Information: Market Information:

## Population a: 8,436,910 (2002).Population a: 8,436,910 (2002).

# # The Global Fund has approved an amount of US$ 6,893,509 to strengthen the fight against Malaria

in Guinea for a period of two years.

Page 18: Malaria Incidence and business oppurunity

5. TOGO5. TOGO CapitalCapital: : LoméLomé MalariaMalaria: : Malaria risk—predominantly due to Malaria risk—predominantly due to P. falciparum—exists throughout the year in theP. falciparum—exists throughout the year in thewhole country. Chloroquine resistant P. falciparumwhole country. Chloroquine resistant P. falciparum reported.reported.

Market InformationMarket Information: : # Population : 4,780,339.# Population : 4,780,339.# Population at Risk of malaria: 100%# Population at Risk of malaria: 100%# Global Fund support to fight Malaria, the country# Global Fund support to fight Malaria, the countryhas applied for the third round.has applied for the third round.

Page 19: Malaria Incidence and business oppurunity

6. SENEGAL6. SENEGAL Capital:Capital: DakarDakar Malaria:Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the Malaria risk—predominantly due to P. falciparum—exists throughout the

year in the whole country. There is less risk from January through June in the central year in the whole country. There is less risk from January through June in the central western regions. Resistance to chloroquine and sulfadoxine– pyrimethamine western regions. Resistance to chloroquine and sulfadoxine– pyrimethamine reported.reported.

Page 20: Malaria Incidence and business oppurunity
Page 21: Malaria Incidence and business oppurunity

MENA CountriesMENA Countries 1. EGYPT Capital Cairo Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the

year in the whole country below 2200 m. There is no risk in Asmara. Resistance to chloroquine and sulfadoxine-pyrimethanine reported.

Page 22: Malaria Incidence and business oppurunity

2. SAUDI ARABIA2. SAUDI ARABIA CapitalCapital RiyadhRiyadh Malaria:Malaria: Malaria risk—predominantly due to P. Malaria risk—predominantly due to P.

falciparum—exists throughout the year in most of the falciparum—exists throughout the year in most of the Southern Region (except in the high-altitude areas of Southern Region (except in the high-altitude areas of Asir Province) and in certain rural areas of the Western Asir Province) and in certain rural areas of the Western Region. No risk in Mecca or Medina cities. Chloroquine-Region. No risk in Mecca or Medina cities. Chloroquine-resistant P. falciparum reported.resistant P. falciparum reported.

3. YEMEN3. YEMEN CapitalCapital Sana’aSana’a MalariaMalaria: : Malaria risk—predominantly due to P. Malaria risk—predominantly due to P.

falciparum—exists throughout the year, but mainly from falciparum—exists throughout the year, but mainly from September through February, in the whole country below September through February, in the whole country below 2000 m. There is no risk in Sana’a city. Resistance to 2000 m. There is no risk in Sana’a city. Resistance to chloroquine reported.chloroquine reported.

Page 23: Malaria Incidence and business oppurunity

4. TURKEY4. TURKEY CapitalCapital AnkaraAnkara Malaria:Malaria: Malaria risk—exclusively due to P. vivax—exists from May to October mainly in Malaria risk—exclusively due to P. vivax—exists from May to October mainly in

the south-eastern part of the country, and in Amikova and Çukurova Plain. There is no the south-eastern part of the country, and in Amikova and Çukurova Plain. There is no malaria risk in the main tourist areas in the west and southwest of the country.malaria risk in the main tourist areas in the west and southwest of the country.

Page 24: Malaria Incidence and business oppurunity

Second PhaseSecond Phase1. VIETNAM Capital: Hanoi Malaria: Malaria risk—predominantly due to P. falciparum—exists in the whole

country, excluding urban centers, the Red River delta, and the coastal plain areas of central Viet Nam. High risk areas are the highland areas below 1500 m south of 18°N, notably the three central highlands provinces of Dak Lak, Gia Lai and Kon Tum, as well as the southern provinces of Ca Mau, Bac Lieu, and Tay Ninh. Resistance to chloroquine, sulfadoxine-pyrimethamine and mefloquine reported.

2. 2. GHANAGHANA CapitalCapital Accra Accra Malaria riskMalaria risk —predominantly due to P. falciparum—exists —predominantly due to P. falciparum—exists

throughout the year in the whole country. Resistance to throughout the year in the whole country. Resistance to chloroquine and sulfadoxine–pyrimethamine reported.chloroquine and sulfadoxine–pyrimethamine reported.

Page 25: Malaria Incidence and business oppurunity

3. SUDAN3. SUDAN CapitalCapital KhartoumKhartoum Malaria:Malaria: Malaria risk—predominantly due to P. falciparum—Malaria risk—predominantly due to P. falciparum—

exists throughout the year in the whole country. Risk is low and exists throughout the year in the whole country. Risk is low and seasonal in the north. It is higher along the Nile south of Lake seasonal in the north. It is higher along the Nile south of Lake Nasser and in the central and southern part of the country. Nasser and in the central and southern part of the country. Malaria risk on the Red Sea coast is very limited. P. falciparum Malaria risk on the Red Sea coast is very limited. P. falciparum resistant to chloroquineresistant to chloroquineand sulfadoxine–pyrimethamine reported.and sulfadoxine–pyrimethamine reported.

4. UGANDA4. UGANDA CapitalCapital KampalaKampala Malaria:Malaria: Malaria risk—predominantly due to P. Malaria risk—predominantly due to P.

falciparum—exists throughout the year in the whole falciparum—exists throughout the year in the whole country including the main towns of Fort Portal, Jinja, country including the main towns of Fort Portal, Jinja, Kampala, Mbale and parts of Kigezi. Resistance to Kampala, Mbale and parts of Kigezi. Resistance to chloroquine and sulfadoxine–pyrimethamine reported.chloroquine and sulfadoxine–pyrimethamine reported.

Page 26: Malaria Incidence and business oppurunity

5. ZAMBIA5. ZAMBIA CapitalCapital LusakaLusaka Market information:Market information: Population : 10,905,879. Global Fund support to fight Malaria: The Global Fund has

approved an amount of US$ 17,892,000 for a period of two years for the project submitted by Zambia.

Malaria:Malaria: Malaria risk—predominantly due to P.falciparam—exists Malaria risk—predominantly due to P.falciparam—exists throughout the year in the whole country. Resistance to chloroquine throughout the year in the whole country. Resistance to chloroquine and sulfadoxine–pyrimethamine reported.and sulfadoxine–pyrimethamine reported.

6. ZIMBABWE6. ZIMBABWE Capital Capital HarareHarare Market Information: Population:13,142,283. Global Fund support to fight Malaria:The Global Fund has

approved an amount of US$ 6,716,250 for a period of two years for the project submitted by Zimbabwe to prevent mortality and reduce morbidity, social and economic losses due to Malaria.

Malaria riskMalaria risk —predominantly due to P. falciparum—exists from —predominantly due to P. falciparum—exists from November through June in areas below 1200 m and throughout the November through June in areas below 1200 m and throughout the by the year in the Zambezi valley. In Harare and Bulawayo, the risk by the year in the Zambezi valley. In Harare and Bulawayo, the risk is negligible. Resistance to chloroquine and sulfadoxine-is negligible. Resistance to chloroquine and sulfadoxine-pyrimethamine reported.pyrimethamine reported.

Page 27: Malaria Incidence and business oppurunity

7. 7. CONGOCONGO CapitalCapital BrazzavilleBrazzaville Malaria:Malaria: Malaria risk—predominantly due to P. falciparum—exists Malaria risk—predominantly due to P. falciparum—exists

throughout the year in the whole country. Resistance to chloroquine throughout the year in the whole country. Resistance to chloroquine and sulfadoxine-pyrimethamine reported.and sulfadoxine-pyrimethamine reported.

Market Information:-Market Information:- # Population : 3,203,662 # Population : 3,203,662 # # Malaria Risk - Population at Risk of malaria 100%

8. 8. CONGO, DEMOCRATIC REPUBLIC OF THE (formerly CONGO, DEMOCRATIC REPUBLIC OF THE (formerly ZAIRE)ZAIRE)

CapitalCapital KinshasaKinshasa Malaria:Malaria: Malaria risk—predominantly due to P. falciparum—Malaria risk—predominantly due to P. falciparum—

exists throughout the year in the whole country. Resistance exists throughout the year in the whole country. Resistance to chloroquine and sulfadoxine–pyrimethamine reported.to chloroquine and sulfadoxine–pyrimethamine reported.

Market Information: Market Information: # Population a: 54,440,8162

Page 28: Malaria Incidence and business oppurunity

THANK YOUTHANK YOUPlease send your feedback to:Please send your feedback to:Priyank DubeyPriyank DubeyApplication SpecialistApplication [email protected]